• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

相似文献

1
Patient-reported symptoms on the antiretroviral regimen efavirenz/emtricitabine/tenofovir.接受依非韦伦/恩曲他滨/替诺福韦治疗方案的患者报告的症状。
AIDS Patient Care STDS. 2012 Jun;26(6):312-9. doi: 10.1089/apc.2012.0044. Epub 2012 May 21.
2
Simplification of antiretroviral therapy to a single-tablet regimen consisting of efavirenz, emtricitabine, and tenofovir disoproxil fumarate versus unmodified antiretroviral therapy in virologically suppressed HIV-1-infected patients.在病毒学抑制的HIV-1感染患者中，将抗逆转录病毒疗法简化为包含依非韦伦、恩曲他滨和替诺福韦酯富马酸盐的单片复方制剂与未调整的抗逆转录病毒疗法的比较。
J Acquir Immune Defic Syndr. 2009 Jun 1;51(2):163-74. doi: 10.1097/QAI.0b013e3181a572cf.
3
Patient-reported outcomes in virologically suppressed, HIV-1-Infected subjects after switching to a simplified, single-tablet regimen of efavirenz, emtricitabine, and tenofovir DF.接受依非韦伦、恩曲他滨和替诺福韦酯简化单片方案治疗后病毒学抑制的 HIV-1 感染者的患者报告结局。
AIDS Patient Care STDS. 2010 Feb;24(2):87-96. doi: 10.1089/apc.2009.0259.
4
Rilpivirine versus efavirenz with emtricitabine/tenofovir disoproxil fumarate in treatment-naïve HIV-1-infected patients with HIV-1 RNA ≤100,000 copies/mL: week 96 pooled ECHO/THRIVE subanalysis.在 HIV-1 RNA≤100000 拷贝/毫升的初治 HIV-1 感染患者中，利匹韦林与依非韦伦联合恩曲他滨/替诺福韦酯治疗：ECHO/THRIVE 亚分析第 96 周汇总。
AIDS Patient Care STDS. 2014 Apr;28(4):168-75. doi: 10.1089/apc.2013.0310. Epub 2014 Mar 24.
5
Safety and efficacy of coformulated efavirenz/emtricitabine/tenofovir single-tablet regimen in treatment-naive patients infected with HIV-1.在初治的 HIV-1 感染者中，使用 coformulated efavirenz/emtricitabine/tenofovir 单片复方制剂的安全性和疗效。
J Med Virol. 2015 Feb;87(2):187-91. doi: 10.1002/jmv.24023. Epub 2014 Jul 28.
6
Efficacy and safety 48 weeks after switching from efavirenz to rilpivirine using emtricitabine/tenofovir disoproxil fumarate-based single-tablet regimens.使用基于恩曲他滨/替诺福韦酯富马酸盐的单片复方制剂从依非韦伦转换为利匹韦林48周后的疗效和安全性。
HIV Clin Trials. 2013 Sep-Oct;14(5):216-23. doi: 10.1310/hct1405-216.
7
Tenofovir disoproxil fumarate, emtricitabine, and efavirenz versus fixed-dose zidovudine/lamivudine and efavirenz in antiretroviral-naive patients: virologic, immunologic, and morphologic changes--a 96-week analysis.初治抗逆转录病毒治疗患者中，替诺福韦酯富马酸盐、恩曲他滨和依非韦伦与固定剂量齐多夫定/拉米夫定和依非韦伦的比较：病毒学、免疫学和形态学变化——一项96周分析
J Acquir Immune Defic Syndr. 2006 Dec 15;43(5):535-40. doi: 10.1097/01.qai.0000245886.51262.67.
8
Randomized, phase 2 evaluation of two single-tablet regimens elvitegravir/cobicistat/emtricitabine/tenofovir disoproxil fumarate versus efavirenz/emtricitabine/tenofovir disoproxil fumarate for the initial treatment of HIV infection.随机、2 期评价两种单一片剂方案：艾维雷韦/考比司他/恩曲他滨/替诺福韦富马酸酯与依非韦伦/恩曲他滨/替诺福韦富马酸酯用于初治 HIV 感染。
AIDS. 2011 Mar 27;25(6):F7-12. doi: 10.1097/QAD.0b013e328345766f.
9
Co-formulated elvitegravir, cobicistat, emtricitabine, and tenofovir versus co-formulated efavirenz, emtricitabine, and tenofovir for initial treatment of HIV-1 infection: a randomised, double-blind, phase 3 trial, analysis of results after 48 weeks.恩曲他滨、替诺福韦、考比司他与艾维雷韦、恩曲他滨、替诺福韦复方制剂用于初治 HIV-1 感染：一项随机、双盲、III 期临床试验，48 周后结果分析。
Lancet. 2012 Jun 30;379(9835):2439-2448. doi: 10.1016/S0140-6736(12)60917-9.
10
A 48-week study of fat molecular alterations in HIV naive patients starting tenofovir/emtricitabine with lopinavir/ritonavir or efavirenz.一项为期 48 周的研究，旨在观察初治 HIV 感染者使用替诺福韦/恩曲他滨联合洛匹那韦/利托那韦或依非韦伦治疗后脂肪分子改变情况。
J Acquir Immune Defic Syndr. 2014 Aug 15;66(5):457-65. doi: 10.1097/QAI.0000000000000205.

引用本文的文献

1
Long-term, bidirectional associations between depressive symptom severity and opioid use among people with HIV: A prospective cohort study.HIV感染者中抑郁症状严重程度与阿片类药物使用之间的长期双向关联：一项前瞻性队列研究。
Addict Behav Rep. 2025 Jun 6;22:100619. doi: 10.1016/j.abrep.2025.100619. eCollection 2025 Dec.
2
Participant-reported Outcomes from the CAPELLA Clinical Trial of Lenacapavir-based Regimens in Heavily Treatment-experienced Adults with HIV.在接受过大量治疗的成年HIV感染者中，基于长效卡帕瑞韦方案的CAPELLA临床试验的受试者报告结局。
AIDS Behav. 2025 May;29(5):1553-1561. doi: 10.1007/s10461-025-04625-x. Epub 2025 Mar 10.
3
Psychometric characteristics of the Spanish version of the HIV Symptom Index.HIV 症状指数西班牙语版的心理测量学特征。
J Patient Rep Outcomes. 2024 Oct 1;8(1):116. doi: 10.1186/s41687-024-00780-2.
4
Prediction of adverse events risk in patients with comorbid post-traumatic stress disorder and alcohol use disorder using electronic medical records by deep learning models.使用深度学习模型通过电子病历预测创伤后应激障碍和酒精使用障碍共病患者的不良事件风险
Drug Alcohol Depend. 2024 Feb 1;255:111066. doi: 10.1016/j.drugalcdep.2023.111066. Epub 2024 Jan 9.
5
Prediction of Adverse Events Risk in Patients with Comorbid Post- Traumatic Stress Disorder and Alcohol Use Disorder Using Electronic Medical Records by Deep Learning Models.利用深度学习模型通过电子病历预测创伤后应激障碍和酒精使用障碍共病患者的不良事件风险
Res Sq. 2023 Sep 18:rs.3.rs-3299369. doi: 10.21203/rs.3.rs-3299369/v1.
6
Factors Associated with Bothersome Symptoms in Individuals With and Without HIV Who Report Alcohol Use.与报告饮酒的 HIV 感染者和非感染者均存在烦扰症状相关的因素。
AIDS Behav. 2023 Jul;27(7):2455-2462. doi: 10.1007/s10461-022-03972-3. Epub 2023 Jan 9.
7
Self-Reported Cannabis Use and HIV Viral Control among Patients with HIV Engaged in Care: Results from a National Cohort Study.自我报告的大麻使用与接受治疗的 HIV 感染者中的 HIV 病毒控制：一项全国队列研究的结果。
Int J Environ Res Public Health. 2022 May 6;19(9):5649. doi: 10.3390/ijerph19095649.
8
Patient-Reported Bothersome Symptoms Attributed to Alcohol Use Among People With and Without HIV.有和没有 HIV 的人群中归因于饮酒的患者报告的令人困扰的症状。
AIDS Behav. 2022 Nov;26(11):3589-3596. doi: 10.1007/s10461-022-03628-2. Epub 2022 May 13.
9
A SMARTTT approach to Treating Tobacco use disorder in persons with HIV (SMARTTT): Rationale and design for a hybrid type 1 effectiveness-implementation study.SMARTTT 方案治疗 HIV 感染者烟草使用障碍（SMARTTT）： 1 型有效性-实施混合研究的原理和设计。
Contemp Clin Trials. 2021 Nov;110:106379. doi: 10.1016/j.cct.2021.106379. Epub 2021 Mar 29.
10
Insights Provided by Depression Screening Regarding Pain, Anxiety, and Substance use in a Veteran Population.抑郁筛查为退伍军人人群的疼痛、焦虑和物质使用提供的见解。
J Prim Care Community Health. 2020 Jan-Dec;11:2150132720949123. doi: 10.1177/2150132720949123.

本文引用的文献

1
Does an index composed of clinical data reflect effects of inflammation, coagulation, and monocyte activation on mortality among those aging with HIV?由临床数据组成的指标是否反映了炎症、凝血和单核细胞活化对老年 HIV 感染者死亡率的影响？
Clin Infect Dis. 2012 Apr;54(7):984-94. doi: 10.1093/cid/cir989. Epub 2012 Feb 15.
2
Association of tenofovir exposure with kidney disease risk in HIV infection.替诺福韦暴露与 HIV 感染相关的肾脏疾病风险。
AIDS. 2012 Apr 24;26(7):867-75. doi: 10.1097/QAD.0b013e328351f68f.
3
Osteoporotic fracture risk associated with cumulative exposure to tenofovir and other antiretroviral agents.与替诺福韦和其他抗逆转录病毒药物累积暴露相关的骨质疏松性骨折风险。
AIDS. 2012 Apr 24;26(7):825-31. doi: 10.1097/QAD.0b013e32835192ae.
4
Long-term treatment with raltegravir or efavirenz combined with tenofovir/emtricitabine for treatment-naive human immunodeficiency virus-1-infected patients: 156-week results from STARTMRK.初治人类免疫缺陷病毒 1 型感染者接受拉替拉韦或依非韦伦联合替诺福韦/恩曲他滨治疗：STARTMRK 的 156 周结果。
Clin Infect Dis. 2011 Oct;53(8):807-16. doi: 10.1093/cid/cir510.
5
Abacavir/lamivudine versus tenofovir DF/emtricitabine as part of combination regimens for initial treatment of HIV: final results.阿巴卡韦/拉米夫定与替诺福韦酯/恩曲他滨联合用于 HIV 初治的方案：最终结果。
J Infect Dis. 2011 Oct 15;204(8):1191-201. doi: 10.1093/infdis/jir505.
6
Severe acute renal failure in an HIV-infected patient after only 2 weeks of tenofovir-based antiretroviral therapy.仅在接受替诺福韦为基础的抗逆转录病毒治疗 2 周后，一名 HIV 感染者出现严重急性肾衰竭。
AIDS Patient Care STDS. 2011 Aug;25(8):457-60. doi: 10.1089/apc.2011.0056. Epub 2011 Jul 13.
7
Comparison of abacavir/lamivudine and tenofovir/emtricitabine among treatment-naive HIV-infected patients initiating therapy.初治 HIV 感染患者中使用阿巴卡韦/拉米夫定和替诺福韦/恩曲他滨的比较。
J Acquir Immune Defic Syndr. 2011 Sep 1;58(1):38-46. doi: 10.1097/QAI.0b013e3182282cfc.
8
Comorbidity acquired before HIV diagnosis and mortality in persons infected and uninfected with HIV: a Danish population-based cohort study.HIV 确诊前获得的合并症与 HIV 感染者和未感染者的死亡率：一项丹麦基于人群的队列研究。
J Acquir Immune Defic Syndr. 2011 Aug 1;57(4):334-9. doi: 10.1097/QAI.0b013e31821d34ed.
9
Quality of life among individuals with HIV starting antiretroviral therapy in diverse resource-limited areas of the world.在全球资源有限的不同地区开始接受抗逆转录病毒治疗的 HIV 感染者的生活质量。
AIDS Behav. 2012 Feb;16(2):266-77. doi: 10.1007/s10461-011-9947-5.
10
Atazanavir plus ritonavir or efavirenz as part of a 3-drug regimen for initial treatment of HIV-1.阿扎那韦联合利托那韦或依非韦伦作为三药方案的一部分，用于 HIV-1 的初始治疗。
Ann Intern Med. 2011 Apr 5;154(7):445-56. doi: 10.7326/0003-4819-154-7-201104050-00316. Epub 2011 Feb 14.

接受依非韦伦/恩曲他滨/替诺福韦治疗方案的患者报告的症状。

Patient-reported symptoms on the antiretroviral regimen efavirenz/emtricitabine/tenofovir.

机构信息

Robert Wood Johnson Foundation Clinical Scholars Program, Yale University School of Medicine, New Haven, Connecticut, USA.

出版信息

AIDS Patient Care STDS. 2012 Jun;26(6):312-9. doi: 10.1089/apc.2012.0044. Epub 2012 May 21.

DOI:10.1089/apc.2012.0044
PMID:22612469
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC3412583/
Abstract

Most patients (80-90%) newly diagnosed with HIV are started on the antiretroviral regimen efavirenz, emtricitabine, and tenofovir (EFV/FTC/TDF). Existing studies of patient tolerability, however, are limited. We compared symptom experiences of patients on EFV/FTC/TDF, and the subsequent impact on health-related quality of life, with those of patients on other combination antiretroviral therapy (cART). We conducted a cross-sectional analysis of the Veterans Aging Cohort Study from February 2008 to August 2009 to compare the symptom experiences of patients on EFV/FTC/TDF vs. other cART, unadjusted and then adjusted for treatment characteristics, and comorbid disease severity. We then assessed the association between EFV/FTC/TDF use and health-related quality of life. Among the 1,759 patients in our analytic sample, EFV/FTC/TDF use was associated with fewer symptoms than was other cART. The use of EFV/FTC/TDF was independently associated with health-related quality of life, and this association was at least partially explained by symptom burden.

摘要

大多数新诊断出 HIV 的患者（80-90%）开始接受依非韦伦、恩曲他滨和替诺福韦（EFV/FTC/TDF）的抗逆转录病毒治疗方案。然而，现有的患者耐受性研究是有限的。我们比较了 EFV/FTC/TDF 治疗的患者的症状体验，以及随后对健康相关生活质量的影响，与其他联合抗逆转录病毒治疗（cART）的患者进行比较。我们对 2008 年 2 月至 2009 年 8 月退伍军人老龄化队列研究进行了横断面分析，比较了 EFV/FTC/TDF 治疗组与其他 cART 治疗组的症状体验，未经调整和调整治疗特征以及合并疾病严重程度后进行比较。然后，我们评估了 EFV/FTC/TDF 使用与健康相关生活质量之间的关系。在我们的分析样本中，1759 名患者中，EFV/FTC/TDF 治疗组的症状少于其他 cART 治疗组。EFV/FTC/TDF 的使用与健康相关生活质量独立相关，这种关联至少部分是由症状负担引起的。